



Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/607,479
Filing Date	June 26, 2003
First Named Inventor	Lawrence S. Young et al.
Art Unit	2845 1632
Examiner Name	Not Yet Assigned
Attorney Docket Number	HARR0032-101

Sheet	1	of	5	Attorney Docket Number
--------------	----------	-----------	----------	-------------------------------

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ^a
		Country Code ³ - Number ⁴ - Kind Code ⁸ (if known)				
SDP	✓ AB	EP 0 939 122 A1	09/01/1999	Universiteit Utrecht		Yes
	✓ AC	WO 91/17773	11/28/1991	Birnstiel et al.		Yes
	✓ AD	WO 91/18088	11/28/1991	Chatterjee and Wong		Yes
	✓ AE	WO 93/08288	04/29/1993	Anlezark et al.		Yes
	✓ AF	WO 93/18759	09/30/1993	Smith and Woo		Yes
	✓ AG	WO 95/02698	01/26/1995	Jessee		Yes
	✓ AH	WO 95/30020	11/09/1995	Midoux et al.		Yes
	/ AI	WO 96/41606	12/27/1996	Thatcher et al.		Yes
	✓ AJ	WO 98/07876	02/26/1998	Antoniou and Grosveld		Yes

- Abstract only

Abstract only

**Examiner
Signature**

Scott J. Priebe

Date Considered

6/30/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08a (08-03)



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3

of 5

Complete if Known

Application Number	10/607,479
Filing Date	June 26, 2003
First Named Inventor	Lawrence S. Young et al.
Art Unit	1645 1632
Examiner Name	Not Yet Assigned
Attorney Docket Number	HARR0032-101

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
SDP	AN	Anderson, W.F., "Human gene therapy," <i>Nature</i> , 392 (Supp):25-30, April 30, 1998	
	AO	Calos, M., "The potential of extrachromosomal replicating vectors for gene therapy," <i>TIG</i> , 12(11):463-466, 1996	
	AP	Chowdhury, J.R. et al., "Long-Term Improvement of Hypercholesterolemia After ex Vivo Gene Therapy in LDLR-Deficient Rabbits," <i>Science</i> , 254:1802-1805, December 20, 1991	
	AQ	Cotton, M. et al., "Receptor-Mediated Transport of DNA into Eukaryotic Cells," <i>Meth. Enzymol.</i> , 217:618-644, 1992	
	AR	Eastman, Q. and Grosschedl, R., "Regulation of LEF-1/TCF transcription factors by Wnt and other signals," <i>Current Opin. Cell Biol.</i> , 11:233-240, 1999	
	AS	Emerson, S.G., "Ex Vivo Expansion of Hematopoietic Precursors, Progenitors, and Stem Cells: The Next Generation of Cellular Therapeutics," <i>Blood</i> , 87(8):3082-3088, April 15, 1996	
	AT	Fallaux, F.J. et al., "New Helper Cells and Matched Early Region 1-Deleted Adenovirus Vectors Prevent Generation of Replication-Competent Adenoviruses," <i>Human Gene Ther.</i> , 9:1909-1917, September 1, 1998	
	AU	Flotte, T.R. et al., "Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector," <i>Proc. Natl. Acad. Sci. USA</i> , 90:10613-10617, November, 1993	
	AV	He, T.C. et al., "Identification of c-MYC as a Target of the APC Pathway," <i>Science</i> , 281:1509-1512, September 4, 1998	
	AW	Hengge, U.R. et al., "Cytokine gene expression in epidermis with biological effects following injection of naked DNA," <i>Nature Genetics</i> , 10:161-166, 1995	
	AX	Hickman, M.A. et al., "Gene Expression Following Direction Injection of DNA into Liver," <i>Human Gene Ther.</i> , 5:1477-1483, December, 1994	
	AY	Hitt, M.M. et al., "Human Adenovirus Vectors for Gene Transfer into Mammalian Cells," <i>Advances in Pharmacology</i> , 40:137-206, 1997	
	AZ	Keown, W.A. et al., "Methods for Introducing DNA into Mammalian Cells," <i>Methods Enzymol.</i> , 185:527-537, 1990	

Examiner Signature	Scott D. Pinke	Date Considered	6/30/05
--------------------	----------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 4

of

5

Complete if Known

Application Number	10/607,479
Filing Date	June 26, 2003
First Named Inventor	Lawrence S. Young et al.
Art Unit	2545-1632
Examiner Name	Not Yet Assigned
Attorney Docket Number	HARR0032-101

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SDP	BA	Korinek, V. et al., "Constitutive Transcriptional Activation by a β -catenin-Tcf Complex in APC ⁺ Colon Carcinoma," <i>Science</i> , 275:1784-1787, March 21, 1997	
	BB	Kuchertapati, R. and Skoultschi, A.I., "Introduction of Purified Genes into Mammalian Cells," <i>Crit. Rev. Biochem.</i> , 16(4):349-379, 1984	
	BC	Lickert, H. et al., "Wnt/ β -catenin signaling regulates the expression of the homeobox gene <i>Cdx1</i> in embryonic intestine," <i>Development</i> , 127:3805-3813, 2000	
	BD	Love, J.J. et al., "Structural basis for DNA bending by the architectural transcription factor LEF-1," <i>Nature</i> , 376:791-795, August 31, 1995	
	BE	Mack, K.D. et al., "Cationic Lipid Enhances In Vitro Receptor-Mediated Transfection," <i>The American Journal of the Medical Sciences</i> , 307(2):138-143, 1994	
	BF	Meyer, K.B. et al., "Intratracheal gene delivery to the mouse airway: characterization of plasmid DNA expression and pharmacokinetics," <i>Gene Therapy</i> , 2:450-460, 1995	
	BG	Morin, P.J. et al., "Activation of β -Catenin-Tcf Signaling in Colon Cancer by Mutations in β -Catenin or APC," <i>Science</i> , 275:1787-1790, March 21, 1997	
	BH	Miller, J.L. et al., "Recombinant adeno-associated virus (rAAV)-mediated expression of a human γ -globin gene in human progenitor-derived erythroid cells," <i>Proc. Natl. Acad. Sci. USA</i> , 91:10183-10187, October, 1994	
	BI	Philip, R. et al., "Efficient and Sustained Gene Expression in Primary T Lymphocytes and Primary and Cultured Tumor Cells Mediated by Adeno-Associated Virus Plasmid DNA Complexed to Cationic Liposomes," <i>Mol. Cell. Biol.</i> , 14(4):2411-2418, April 1994	
	BJ	Plank, C. et al., "The Influenced of Endosome-disruptive Peptides on Gene Transfer Using Synthetic Virus-like Gene Transfer Systems," <i>J. Biol. Chem.</i> , 269(17):12918-12924, April 29, 1994	
	BK	Russell, D.W. et al., "Adeno-associated virus vectors preferentially transduced cells in S phase," <i>Proc. Natl. Acad. Sci. USA</i> , 91:8915-8919, September, 1994	
	BL	Shtutman, M. et al., "The cyclin D1 gene is a target of the β -catenin/LEF-1 pathway," <i>Proc. Natl. Acad. Sci. USA</i> , 96:5522-5527, May, 1999	
	BM	Sikes, M.L. et al., "In Vivo Transfer into Rabbit Thyroid Follicular Cells by Direct DNA Injection," <i>Human Gene Ther.</i> , 5:837-844, 1994	

Examiner
Signature

Scott D. Pinko

Date
Considered

6/30/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 5 of 5

Complete If Known

Application Number	10/607,479
Filing Date	June 26, 2003
First Named Inventor	Lawrence S. Young et al.
Art Unit	1845 / 632
Examiner Name	Not Yet Assigned
Attorney Docket Number	HARR0032-101

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
SDP	BN	Tetsu, O. and McCormick, F., "β-Catenin regulates expression of cyclin D1 in colon carcinoma cells," <i>Nature</i> , 398:422-426, April 1, 1999	
	BO	Trubetsky, V.S. et al., "Use of N-Terminal Modified Poly(L-lysine)-Antibody Conjugate as a Carrier for Targeted Gene Delivery in Mouse Lung Endothelial Cells," <i>Bioconjugate Chem.</i> , 3:323-327, 1992	
	BP	Ustav, M. and Stenlund, A., "Transient replication of BPV-1 requires two viral polypeptides encoded by the E1 and E2 open reading frames," <i>The EMBO J.</i> , 10(2):449-457, 1991	
	BQ	van de Wetering, M. et al., "Identification and cloning of TCF-1, a T lymphocyte-specific transcription factor containing a sequence-specific HMG box," <i>The EMBO J.</i> , 10(1):123-132, 1991	
	BR	Vile, R.G. and Hart, I.R., "In Vitro and in Vivo Targeting of Gene Expression to Melanoma Cells," <i>Cancer Res.</i> , 53:962-967, 1993	
	BS	Walsh, C.E. et al., "Regulated high level expression of a human γ-globin gene introduced into erythroid cells by an adeno-associated virus vector," <i>Proc. Natl. Acad. Sci. USA</i> , 89:7257-7261, August, 1992	
	BT	Watanabe, M. et al., "Nucleotide sequence of <i>Salmonella typhimurium</i> nitroreductase gene," <i>Nucleic Acids Res.</i> , 18(4):1059, 1990	
	BU	Wilson, J.M. et al., "Ex Vivo Gene Therapy of Familial Hypercholesterolemia," <i>Human Gene Ther.</i> , 3:179-222, 1992	
	BV	Wilson, J.M. et al., "Hepatocyte-directed Gene Transfer in vivo Leads to Transient Improvement of Hypercholesterolemia in Low Density Lipoprotein Receptor-deficient Rabbits," <i>J. Biol. Chem.</i> , 267(2):963-967, January 15, 1992	
	BW	Wolff, J.A. et al., "Direct Gene Transfer into Mouse Muscle in Vivo," <i>Science</i> , 247:1465-1468, March 23, 1990	
	BX	Wu and Wu, "Receptor-mediated Gene Delivery and Expression in Vivo," <i>J. Biol. Chem.</i> , 263(29):14621-14624, October 15, 1988	

Examiner
Signature

Scott D. Pinski

Date
Considered

6/30/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.